Eldecalcitol is superior to alfacalcidol in maintaining bone mineral density in glucocorticoid-induced osteoporosis patients (e-GLORIA)

Introduction Eldecalcitol increases bone mineral density (BMD) and reduces vertebral fracture in patients with primary osteoporosis. However, the effect of eldecalcitol on BMD and fracture in glucocorticoid-induced osteoporosis (GIO) patients is unknown. This study was undertaken to compare the effe...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of bone and mineral metabolism 2020-07, Vol.38 (4), p.522-532
Hauptverfasser:	Matsumoto, Toshio, Yamamoto, Kazuhiko, Takeuchi, Tsutomu, Tanaka, Yoshiya, Tanaka, Sakae, Nakano, Tetsuo, Ito, Masako, Tomomitsu, Tatsushi, Hirakawa, Akihiro, Soen, Satoshi
Format:	Artikel
Sprache:	eng
Schlagworte:	Biomarkers - metabolism Bone density Bone Density - drug effects Bone Density Conservation Agents - therapeutic use Bone growth Bone mineral density Bone Remodeling - drug effects Bone resorption Female Femur Neck - drug effects Femur Neck - physiopathology Fractures Glucocorticoids Glucocorticoids - adverse effects Hip - physiopathology Humans Hydroxycholecalciferols - adverse effects Hydroxycholecalciferols - pharmacology Hydroxycholecalciferols - therapeutic use Kaplan-Meier Estimate Lumbar Vertebrae - drug effects Lumbar Vertebrae - physiopathology Male Medicine Medicine & Public Health Metabolic Diseases Middle Aged Original Article Orthopedics Osteogenesis Osteoporosis Osteoporosis - drug therapy Osteoporosis - physiopathology Patients Spinal Fractures - epidemiology Spine (lumbar) Vertebrae Vitamin D - adverse effects Vitamin D - analogs & derivatives Vitamin D - pharmacology Vitamin D - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Introduction Eldecalcitol increases bone mineral density (BMD) and reduces vertebral fracture in patients with primary osteoporosis. However, the effect of eldecalcitol on BMD and fracture in glucocorticoid-induced osteoporosis (GIO) patients is unknown. This study was undertaken to compare the effect of eldecalcitol on BMD and fracture with that of alfacalcidol in GIO patients. Materials and methods A randomized, open-label, parallel group study was conducted to identify the effectiveness and safety of monotherapy with 0.75 μg eldecalcitol compared with 1.0 μg alfacalcidol in GIO patients. Results Lumbar spine BMD increased with eldecalcitol, but decreased with alfacalcidol at 12 and 24 months (between group difference 1.29%, p
ISSN:	0914-8779 1435-5604
DOI:	10.1007/s00774-020-01091-4